GlassScriptPhysician profile
Leronda Decamp
NPI 1689197212
$7,259.09
in general payments reported to CMS, 2019-2025
15 companies · $2,597 in 2025
The $2,597 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $400 · 2022: $1,041 · 2023: $1,306 · 2024: $1,916 · 2025: $2,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,818.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,581.82 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $1,090.22 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $807.39 | 2022-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $713.33 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $413.48 | 2021-2025 | Caplyta |
| Abbvie INC. | $349.02 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $315.40 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $239.72 | 2023 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $198.09 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $154.52 | 2024-2025 | Austedo Xr, Uzedy |
| Viiv Healthcare Company | $125.00 | 2025 | Cabenuva |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $125.00 | 2025 | |
| Corium, LLC | $72.90 | 2022-2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $45.30 | 2024-2025 | Fanapt |
| Aveo Pharmaceuticals, INC. | $27.90 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leronda Decamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.